Association of leptin and leptin receptor gene polymorphisms with hypertension: a Meta-analysis

Abstract

Abstract:

AIM: To evaluate the association between leptin gene and leptin receptor gene polymorphisms with hypertension. METHODS: CNKI, Wanfang database, Chongqing VIP network, Pubmed database and EMBASE database were researched. The data on the relationship between leptin/its receptor gene and hypertension were extracted and evaluated by software STATA11.0. RESULTS: Twenty-one studies involving 4 736 patients and 3 096 healthy people were included. The meta-analysis showed the II/I polymorphism of LEP gene was associated with hypertension in recessive genetic model and additive genetic model (recessive genetic model: OR=2.16, 95%CI=1.08-4.31, P=0.029, additive genetic model: OR=2.27, 95%CI=1.08-4.79, P=0.031); the Gln223Arg polymorphism of LEPR gene was associated with hypertension in dominant model and allelic model (dominant model: OR=1.55, 95%CI=1.14-2.11, P=0.005; allelic model: OR=1.36，95%CI=1.09-1.71, P=0.007). No statistically significant correlation was found between the Lys109Arg polymorphism of LEPR gene and hypertension (dominant model: OR=0.87, 95%CI=0.67-1.14, P=0.307, recessive genetic model: OR=0.91, 95%CI=0.70-1.20, P=0.099, additive genetic model: OR=0.92, 95%CI=0.70-1.21, P=0.071, allelic model: OR=1.04, 95%CI=0.80-1.35, P=0.830). CONCLUSION: There is no significant correlation between Lys109Arg polymorphism of LEPR gene and hypertension, but the II/I polymorphism of LEP gene and Gln223Arg polymorphism of LEPR gene are associated with hypertension.

Key words: hypertension, leptin, leptin receptor, gene polymorphism, Meta-analysis

CLC Number:

R544.1

ZHANG Xiaoyu, FANG Zhengmei, YAO Yingshui. Association of leptin and leptin receptor gene polymorphisms with hypertension: a Meta-analysis[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(8): 910-916.

References

［1］Della-Morte D, Guadagni F, Palmirotta R, et al. Genetics of ischemic stroke, stroke-related risk factors, stroke precursors and treatments［J］. Pharmacogenomics, 2012, 13(5): 595-613.
［2］纪智，郭文，朱华超，等. 以基因芯片探究针刺泻法对应激性高血压前期大鼠肾脏基因表达的影响［J］. 长春中医药大学学报，2016, 32(3): 458-461.
［3］Harlan SM, Rahmouni K. Neuroanatomical determinants of the sympathetic nerve responses evoked by leptin ［J］. Clin Auton Res, 2013, 23(1): 1-7.
［4］Mark AL. Selective leptin resistance revisited［J］. Am J Physiol Regul Integr Comp Physiol, 2013, 305(6): R566-581.
［5］Agata J, Masuda A, Takada M, et al. High plasma immunoreactive leptin level in essential hypertension［J］. Am J Hypertens, 1997, 10(10): 1171-1174.
［6］谢平，邓振霞，许岚. Ⅱ型糖尿病患者瘦素受体基因变异与肥胖及高血压的相关性研究［J］. 中国优生与遗传杂志，2002, 10(6): 34-35.
［7］吴红赤，王明奡. 瘦素受体基因多态性与高血压肾损害及肾实质性高血压［J］. 中华医学杂志，2004, 84(11): 36-38.
［8］王楠，成蓓，马丽雅. 原发性高血压患者左心室功能及临床变量与瘦素受体基因变异的关系［J］. 临床心血管病杂志，2007, 23(4): 259-261.
［9］施有为，张艳斌，罗昭峰，等. 高血压胰岛素抵抗与瘦素受体基因变异的研究［J］. 中华内科杂志，2007, 46(3): 238-239.
［10］潘若望，石南松，张恩勇，等. 瘦素受体基因Gln223Arg多态性与温州地区高血压合并肥胖的相关性研究［J］. 解放军医学杂志，2008, 33(10): 1192-1194.
［11］赵林双，向光大，唐瑛，等. 武汉地区高血压合并肥胖与瘦素受体基因GIN223Arg变异的关系［J］. 中国慢性病预防与控制，2007, 15(2): 91-94.
［12］顾萍，蒋卫民，王坚，等. 瘦素受体基因多态性与高血压病及其临床代谢特征的相关性研究［J］. 临床内科杂志，2009, 26(11): 762-765.
［13］王楠，成蓓，马丽雅. 高血压患者左心室功能及肾脏血流动力学与瘦素受体基因外显子4Lys109Arg变异的关系［J］. 中国医师进修杂志，2010, 33(1): 13-15.
［14］蔡泽园，赵福梅，刘婷，等. 瘦素受体基因多态性与原发性高血压及血脂的关系［J］. 天津医药，2011, 39(3): 196-198.
［15］包博侃，应俊，张洪勤，等. 瘦素受体基因Lys109Arg多态性与温州地区高血压合并肥胖的相关性研究［J］. 中国优生与遗传杂志，2010, 40(12): 20-22.
［16］王先梅，李春城，杨丽霞. 瘦素受体基因多态性与云南地区高血压合并肥胖的相关性［J］. 中国动脉硬化杂志，2012, 20(11): 1007-1012.
［17］高丽，管立学，李海波，等. 瘦素受体基因3057位G→A变异与妊娠高血压综合征的关系［J］. 中国优生与遗传杂志，2009,17 (10): 23-24.
［18］Liu Y, Lou YQ, Liu K, et al. Role of leptin receptor gene polymorphisms in susceptibility to the development of essential hypertension: a case-control association study in a Northern Han Chinese population［J］. J Hum Hypertens, 2014, 28(9): 551-556.
［19］Gu P, Jiang W, Chen M, et al. Association of leptin receptor gene polymorphisms and essential hypertension in a Chinese population［J］. J Endocrinol Invest, 2012, 35(9): 859-865.
［20］Das B, Pawar N, Saini D, et al. Genetic association study of selected candidate genes (ApoB, LPL, Leptin) and telomere length in obese and hypertensive individuals［J］. BMC Med Genet, 2009, 10(1): 99.
［21］Shintani M, Ikegami H, Fujisawa T, et al. Leptin gene polymorphism is associated with hypertension independent of obesity ［J］. J Clin Endocrinol Metab, 2002, 87(6): 2909-2912.
［22］Maestrini S, Mencarelli M, Verti B, et al. Lack of association between the tetranucleotide repeat polymorphism in the 3'-flanking region of the leptin gene and hypertension in severely obese patients［J］. J Endocrinol Invest, 2006, 29(9): 776-780.
［23］Akhter Q, Masood A, Ashraf R, et al. Polymorphisms in the 3'UTR of the human leptin gene and their role in hypertension［J］. Mol Med Rep, 2012, 5(4): 1058-1062.
［24］Nagalingam S, Uppuluri MV, Gunda P, et al. Evaluation of leptin and leptin receptor gene 3' UTR polymorphisms in essential hypertension［J］. Clin Exp Hypertens, 2014, 36(6): 419-425.
［25］Wiedemann A, Vocke F, Fitzgerald JS, ea al. Leptin gene (TTTC)(n) microsatellite polymorphism as well as leptin receptor R223Q and PPARgamma2 P12A substitutions are not associated with hypertensive disorders in pregnancy［J］. Am J Reprod Immunol, 2010, 63(4): 310-317.
［26］Tennekoon KH, Indika WL, Sugathadasa R, et al. LEPR c.668A>G polymorphism in a cohort of Sri Lankan women with pre-eclampsia / pregnancy induced hypertension: a case control study ［J］. BMC Res Notes, 2012, 5(1): 308.
［27］Winters B, Mo Z, Brooks-Asplund E, et al. Reduction of obesity, as induced by leptin, reverses endothelial dysfunction in obese (Lep(ob)) mice［J］. J Appl Physiol (1985), 2000, 89(6): 2382-2390.
［28］Schutte R, Huisman HW, Schutte AE, et al. Leptin is independently associated with systolic blood pressure, pulse pressure and arterial compliance in hypertensive African women with increased adiposity: the POWIRS study ［J］. J Hum Hypertens, 2005, 19(7): 535-541.
［29］Pena Gd, Guimares AL, Veloso RR, et al. Leptin receptor gene Gln223Arg Polymorphism is not associated with hypertension: a preliminary population-based cross-sectional study［J］. Cardiol Res Pract, 2014, 2014(3): 879037.

[1]	LI Qinghua, ZHAO Yan, ZHAO Haigang, GAO Pengfei, XU Bingxin. Value of ABCB1 G2677T gene polymorphism detection in lipid-lowering therapy with atorvastatin in patients suffered from ischemic stroke [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 633-640.
[2]	ZHU Li, WEI Bing, LIAO Shi'e, ZHANG Chao, ZHENG Xiaoyu, LIU Yajun. Effects of single nucleotide polymorphism of drug metabolizing enzyme cytochrome P450 on the efficacy of inhaled cortisol hormone in asthmatic children [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 536-543.
[3]	ZHANG Zhiying, JIN Xiuhong, ZHANG Xiaoning, ZHANG Xiangfeng, LUO Qinglin, ZHANG Songlin. Clinical study of TBX21 and ADCY9 polymorphisms in the develop- ment of childhood asthma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 407-412.
[4]	NING Sisi, ZHAO Yuhong, YAN Lei, TANG Minna, ZHANG Ningzhi, ZHANG Yongqiao, CUI Zhaoqiang. Controversies over the targets of controlling blood pressure in hyper- tensive patients with chronic kidney disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 463-467.
[5]	MA Guangli, ZHANG Jing. Application of quantitative pharmacology in vaccine research and de-velopment: overview and prospect [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 315-322.
[6]	SHEN Chang, AI Kelong, HU Changping. Research progress in the regulation of hypoxic pulmonary hypertension by hypoxia-inducible factor-1 signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 114-120.
[7]	YE Hongbo, SONG Yangyang, XUE Ling, RUI Jianzhong. Meropenem population pharmacokinetic model for the Chinese elderly established by model-based META analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 984-990.
[8]	FU Hong, TIAN Lei. Individualized precision therapy for patients with ischemic stroke and hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 870-876.
[9]	CHEN Wengang, YIN Qin, ZHANG Weiwei, ZHOU Lulu, KOU Wanqing, YUAN Xiaolong. Distributions of MTHFR gene polymorphism and its correlation with blood Hcy in patients with hypertension in southern Anhui province [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 768-774.
[10]	WU Yuanzhu, LIU Jun, YANG Kui, PENG Jing, LUAN Jiajie, WEI Jun, ZHANG Dafa, SONG Shuai, YUAN Xiaolong, WANG Zhongfang, ZHANG Nianbao, XIE Dan, JIANG Peng, FAN Jie. Distribution of CYP2C9*3 and VKORC1-1639G>A gene polymorphism in Anhui Han population and their influence on the stable dose of warfarin [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 652-659.
[11]	ZHANG Ningzhi, ZHAO Yuhong, TANG Minna, ZHANG Yongqiao, NING Sisi, CUI Zhaoqiang. Application of chronopharmacology in the hypertension treatment [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 418-422.
[12]	CUI Sumei, CUI Zhaoqiang. Application of β-blockers for hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 423-427.
[13]	LI Yuanfang, CUI Zhaoqiang. Treatment of hypertension complicated with hyperuricemia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 428-432.
[14]	XU Jianfei, LIN Li. Research progress in pharmacological and non-pharmacological treatments of hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 433-441.
[15]	KUAI Zheng, ZHANG Xiaoyi, ZOU Yunzeng. Angiotensin receptor neprilysin inhibitor in elderly with hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 442-445.